




The relative strengths and weaknesses of Cytomx Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytomx Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 6.5% points. The greatest weakness of Cytomx Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 113% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	237,102	Assets	260,891
Cost of Goods Sold	0	Liabilities	346,642
Intangible Assets	949	Expenses	154,498
Liabilities, Current	152,608	Revenues	53,163
Liabilities, Non-Current	194,034	Stockholders Equity	-85,751
Other Assets	17,768	Net Income	-99,317
Other Compr. Net Income	252	Comprehensive Net Income	-99,191
Other Expenses	0	BaseVar	408,732
Other Liabilities	0	ECR before LimitedLiability	-94%
Other Net Income	2,018	Economic Capital Ratio	131%
Other Revenues	53,163		
Property and Equipment	5,072		
Research and Development	111,649		
Selling, General and Administrative Expense	42,849		